Chemoenzymatic glycoengineering of antibodies and Fc fragments thereof
AssigneeUniversity of Maryland, Baltimore
InventorsLai-Xi Wang, Wei Huang
Life of this patent
Estimating the term…
Abstract
The present invention provides for recombinant Endo-S mutants that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sialylated oxazoline or synthetic oligosaccharide oxazoline is added to a core fucosylated or nonfucosylated GlcNAc-protein acceptor. Such recombinant Endo-S mutants are useful for efficient glycosylation remodeling of IgG1-Fc domain to provide different antibody glycoforms carrying structurally well-defined Fc N-glycans.
Claims1
A composition comprising at least one Streptococcus pyogenes Endo-S Asp-233 mutant selected from the group consisting of SEQ ID NO:2 (D233Q) and SEQ ID NO:
- 3 (D233A) and a tris or phosphate buffer.
Dependencies are inferred from the claim text.